A retrospective real-world study demonstrated that lenvatinib combined with programmed death-1 (PD-1) inhibitors achieved a notable median overall survival of 17.8 months in previously treated unresectable hepatocellular carcinoma (uHCC) patients (10). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.